Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to ...

Elective, or planned, surgery accounts for around 70% of hospital admissions, and two thirds of these surgeries take place in private hospitals. In Australia, you can choose between the public and ...

The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models.

Business Highlights Heron's Acute Care franchise delivered revenue growth of 55.5% year-over-year in Q2 2025 and 70.5% year-over-year for the first half of 2025, reflecting continued commercial ...

The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models. Capital Allocation The ...

Provided by PR NewswireAug 8, 2025, 11:45:00 AM Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile ...

Viatris Inc. (Nasdaq: VTRS) today reported strong second quarter 2025 financial results and reiterated its 2025 financial guidance ranges across all metrics.

Aim: External genitalia swellings represent diagnostic and treatment challenges in equids. Thus, the present study aimed to describe the clinical, histopathological, and treatment outcomes of external ...

Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association ...